Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.

Read More »

Genentech’s Satralizumab Shows Strong Results in Rare CNS Disorder

Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.

Read More »

New Data Presented at ECTRIMS Reinforce Long-term Benefits of Tecfidera Over 10 Years

Biogen Inc. announced new data to support the consistent, long-term benefits of treatment with Tecfidera (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis.

Read More »

U.S. prices for multiple sclerosis drugs are on the rise

A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.

Read More »

Amgen to buy Celgene psoriasis drug Otezla

Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with the company’s $74 billion deal for Celgene by the end of 2019.

Read More »

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

U.S. FDA Expands Regulatory Approvals for LEO Pharma’s Enstilar Foam and Taclonex Topical Suspension in Treatment of Plaque Psoriasis

LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.

Read More »

Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial

In a Phase III head-to-head trial, Janssen Pharmaceutical’s ponesimod stood up to Sanofi’s Aubagio (teriflunomide) in adults with relapsing multiple sclerosis.

Read More »

Scientists Identify Differences Between Relapsing/Remitting and Progressive Multiple Sclerosis

Researchers with City University of New York and the Icahn School of Medicine at Mount Sinai identified specific biological differences between relapsing-remitting MS (RRMS) – in which patients often go into clinical remission – and progression MS, which has the potential to lead to new therapeutic approaches and diagnostic testing.

Read More »

Genentech Strikes Three Drug Discovery Deals

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom